Investor alert: class action lawsuit filed on behalf of pepgen inc. (pepg) investors – holzer & holzer, llc encourages investors with significant losses to contact the firm

Atlanta, june 10, 2025 (globe newswire) -- a shareholder class action lawsuit has been filed against pepgen inc. (“pepgen” or the “company”) (nasdaq: pepg). the lawsuit alleges that defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about pepgen's business, operations, and prospects, including allegations that: (i) pgn-edo51 was less effective and safe than defendants had led investors to believe; (ii) the connect2 study was deficient for purposes of u.s. food and drug administration (“fda”) approval; and (iii) as a result of all the foregoing, pepgen was likely to halt the connect2 study, and pgn-edo51's clinical, regulatory, and commercial prospects were overstated.
PEPG Ratings Summary
PEPG Quant Ranking